June 22, 2010
ImmunoGen, Inc. Announces Vice President Promotions in Product Development

WALTHAM, Mass., Jun 22, 2010 (BUSINESS WIRE) --ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the promotion to vice president of two executive directors - Godfrey Amphlett, Ph.D., and Robert J. Lutz, Ph.D. - who have played central roles in establishing ImmunoGen's highly successful product development capabilities. These functions complement the Company's strong research capabilities in ImmunoGen's advancement of its own novel anticancer compounds and the industry-leading target-to-commercial product expertise the Company provides to its partners.

"Over the past few years, Bob and Godfrey have led the transformation of functions that enable us to successfully build and advance our proprietary product pipeline as well as provide industry-leading support to our partners," commented Daniel Junius, President and Chief Executive Officer. "ImmunoGen has transitioned from being an organization with strong research to one with equally productive - and unique - development capabilities."

Godfrey Amphlett, Ph.D., Vice President, Process and Analytical Development

Since joining ImmunoGen in 2001, Dr. Amphlett has built a team with industry-leading expertise in the many areas critical to transforming a promising research compound into a commercially-manufacturable, approvable product. These include process development, formulation development, characterization and analytical methods for both the individual product components as well as for the complete drug product. For example, his team developed the commercial-scale production processes for trastuzumab-DM1 (T-DM1) and SAR3419 for Genentech and sanofi-aventis, respectively.

Prior to joining ImmunoGen in 2001, Dr. Amphlett held positions of increasing responsibility at Genetics Institute, now a part of Pfizer, and at Armour Pharmaceuticals, a subsidiary of Revlon Health Care. He earned a B.A. from the University of Cambridge, England, and a Ph.D. from the University of Birmingham, England. Dr. Amphlett did his postdoctoral work at the University of Notre Dame, South Bend, IN.

Robert J. Lutz, Ph.D., Vice President, Translational Research and Development

Dr. Lutz has held positions of increasing responsibility since joining ImmunoGen as a Scientist in 1992. He gained broad responsibility for ImmunoGen's preclinical development functions with his promotion to Senior Director of Preclinical Development in 2004 and to Executive Director, Preclinical Development in 2007. In early 2010, he gained added responsibility for project management, becoming Executive Director, Drug Development.

Dr. Lutz leads functions that provide support essential to the successful advancement of ImmunoGen and partner new product candidates from research through clinical development and the leveraging of findings in the clinic to further enhance ImmunoGen's proprietary product pipeline. He earned a B.S. from the University of New Hampshire, NH, and a Ph.D. from Brandeis University, MA. Dr. Lutz did his postdoctoral work at the Eleanor Roosevelt Institute for Cancer Research, Denver, CO.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumors. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, T-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer Schering Pharma and Amgen. More information about ImmunoGen can be found at

SOURCE: ImmunoGen

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
For Media:
The Yates Network
Barbara Yates, 781-258-6153 



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?